13 GHP Biotechnology Awards 2024 ith a long-standing customer portfolio including industry innovators such as Moderna and Editas Medicine, Azzur Group, LLC has enabled considerable growth and clinical success over recent years. Underpinning this success was the launch of Azzur Cleanrooms on Demand(™), a hybrid manufacturing capacity model designed to pre-empt and overcome the challenges faced with niche, specialist product development and manufacturing, such as the need for flexibility, the ability to pivot priorities, and speed to clinical and commercial milestones. Additionally, Azzur Group recently launched analytical lab testing capabilities for advanced therapeutic medicinal products (ATMPs). Having announced this new investment in February, Stevens comments, “More than 3,000 advanced therapies and treatments are already in the global pipeline. Azzur’s new ATMP holistic, platform service encapsulates manufacturing infrastructure, expertise and testing capability that meets the continuum of demand across the development to commercial lifecycle. This model ensures risk mitigation, flexibility and absolute IP protection for innovators within fit for phase and scale infrastructure. Azzur was founded as a premier GMP consulting firm in 2010, specializing in the compliance needs of clients in the regulated space. In 2012, the organization added Azzur Labs, which provides microbiology and analytical lab services tailored to the needs of the life science community. It is this array of solutions, combined with a unique ability to help clients operate across all aspects of a multi-faceted drug pipeline, that truly distinguishes the business. As Stevens explains, “We continue to evolve to support customers throughout the entire process, offering solutions to help start, scale, and sustain their GMP [good manufacturing practice] business.” As Stevens tells us, “Azzur Group sets its clients up for success with the strategies, processes, and people to manage risk, enhance quality, and maintain regulatory compliance.” Elaborating further, Stevens states, “We feel optimistic about a 2024 financial rebound, and see that strategies such as partnerships and creative collaborations are increasingly important, along with pragmatic and thoughtful approaches to investing in early-stage progress of treatments and therapies.” Azzur Groups unique ways of enabling such strategies become even more relevant, Stevens explains, “in addition to our fully operational cleanroom infrastructure, testing capabilities and expertise, our consulting team can support end-to-end - from working with academia and healthcare operations to ensure that they are well-equipped to comply with good manufacturing practices and have the available laboratory space required to manufacture batches in sufficient quantities for clinical trials, through to commercialisation.” Headquartered in Hatboro, Pennsylvania, Azzur Group, LLC has played an instrumental role in supporting the biopharma community and progressing advanced therapeutics from development to patient. Bolstered by almost four decades of innovative service to the life sciences sector, the company is a trusted partner to some of the world’s most pioneering biopharma, medical device and associated healthcare technology companies. Sarah Stevens, President, tells us more. Best Early-Phase BioTech Manufacturing Firm 2024 - North America & GHP Innovation Excellence Award 2024 “By working with Azzur Group, companies can progress and succeed flexibly and at speed whilst minimising risk ” Steven said. We agree with this sentiment and are proud to bestow Azzur Group, LLC, with two prestigious awards celebrating its innovation, excellence, and skill in this sphere. Contact: Katie Brown Company: Azzur Group, LLC Web Address: https://azzur.com/ W Azzur Group, LLC
RkJQdWJsaXNoZXIy MTUyMDQwMA==